Background Medial meniscus posterior root tears (MMPRTs) significantly contribute to knee dysfunction, leading to abnormal biomechanics and accelerated cartilage degeneration. Arthroscopic transtibial pullout and all-inside repair are two commonly used techniques for treating MMPRTs, each with unique advantages and limitations. Objective To compare the clinical and functional outcomes of the transtibial pullout and all-inside repair techniques in the treatment of MMPRTs, with a focus on postoperative recovery, knee function, and complications. Methods 40 patients with MMPRTs were randomized to undergo either the transtibial pullout or all-inside repair technique. Clinical outcomes were evaluated using the International Knee Documentation Committee (IKDC) score, Tegner activity scale, Lysholm score, and active range of motion (AROM) of knee flexion, both before and after surgery. Data on operative time, time to ambulation, hospital stay duration, and complications were also collected. Results Both surgical groups showed significant improvements in clinical outcomes postoperatively (p<0.001). The transtibial group exhibited greater functional recovery, with IKDC, Tegner, and Lysholm scores improving by approximately 60%, 110%, and 68%, respectively, compared to the all-inside group. However, complications were more frequent in the transtibial group, including three cases of wound healing issues and one infection, while the all-inside group had one case of deep vein thrombosis. No re-tears were observed in either group during follow-up. Conclusion Both the transtibial pullout and all-inside repair techniques effectively restore knee function in patients with MMPRTs. While the transtibial pullout provides better functional outcomes, it is associated with a higher complication rate. The choice of surgical approach should consider patient-specific factors, including tear characteristics and overall health, to optimize results.

Background Osteosarcoma (OS) has been the most common malignancy of the bone in children and adolescents, and the unsatisfactory prognosis of OS sufferers has long been a hard nut. Here, we delved into the markers with a prognostic value for predicting the prognosis of OS patients. Methods The messenger RNA (mRNA) sequencing data and clinical data of OS were retrieved from a Gene Expression Omnibus (GEO) dataset (GSE39058). Next, prognosis-related genes (PRGs) were filtered with the aid of Kaplan–Meier (K-M) curves and Cox regression analysis (CRA). Later, Gene Ontology (GO) biological process analysis was used in verifying the function of different genes. CCK-8 and cell apoptosis assay were performed to evaluate the function of MFNG in U2OS cells. Results Among the obtained genes, Manic Fringe ( MFNG ) had the closest relevance to prognosis and clinical traits, thus becoming the research object herein. In light of the expression level of MFNG , patients fell into high- and low- MFNG groups. Patients with elevated MFNG expression had a worse prognosis, according to the survival analysis. It was unveiled by the univariate and multivariate analyses that MFNG expression was an independent adverse prognostic factor for disease-free survival in OS patients (p = 0.006). Meanwhile, MFNG expression was linked to gender and tumor recurrence, and it was higher in patients with OS recurrence. Moreover, overexpression of MFNG promoted the cell proliferation and inhibited the cell apoptosis of U2OS cells. Conclusions The expression level of MFNG negatively correlated with OS progression, and as an independent adverse prognostic factor for disease-free survival in OS patients. Moreover, MFNG regulated the cell proliferation and apoptosis of OS cells.

目的 比较关节镜下前交叉韧带重建术中股骨侧应用固定袢与可调节钛板的临床效果.方法 回顾性分析自2015-01-2020-05采用关节镜下前交叉韧带重建术治疗的49例单侧前交叉韧带损伤,其中24例股骨侧采用固定袢装置固定(EB组),25例股骨侧采用可调节钛板装置固定(RL组).比较2组IKDC评分、Lysholm评分以及KT-1000关节测量仪测量的患侧胫骨前移距离、双膝胫骨前移距离差值.结果 49例均获得至少2年的随访,随访时间(26±2)个月.术后6个月时2组Lysholm评分、IKDC评分、患侧胫骨前移距离、双膝胫骨前移距离差值均较术前显著改善,差异有统计学意义(P＜0.05).术后6个月时EB组的Lysholm评分比RL组高,差异有统计学意义(P＜0.05),2组的IKDC评分、患侧胫骨前移距离、双膝胫骨前移距离差值差异无统计学意义(P＞0.05);术后2年时RL组的双膝胫骨前移距离差值比EB组小,差异有统计学意义(P＜0.05),2组的IKDC评分、Lysholm评分、患侧胫骨前移距离差异无统计学意义(P＞0.05).结论 关节镜下前交叉韧带重建术中股骨侧应用固定袢与可调节钛板的效果相当,都能得到良好的临床疗效.

[目的]探讨Rigidloop悬吊钛板双束重建喙锁韧带治疗RockwoodⅢ型肩锁关节脱位的效果.[方法]回顾性研究本院在2019年6月-2020年6月因Rockwood Ⅲ型肩锁关节脱位接受手术治疗的48例患者的临床资料,按术前医患沟通结果,22例采用钩钢板固定,26例采用Rigidloop重建喙锁韧带.比较两组围手术期、随访和影像指标.[结果]两组患者均顺利完成手术,两组手术时间的差异无统计学意义(P＞0.05).重建组切口总长度[(4.3±0.5)cmvs(7.0±0.8)cm,P＜0.05]、术中失血量[(62.0±15.8)ml vs(97.1±26.5)ml,P＜0.05]、住院时间[(11.1±2.3)d vs(14.3±2.9)d,P＜0.05]均显著优于钩板组.随术后早期时间推移,VAS评分均显著降低(P＜0.05),CRP显著增加(P＜0.05),但IL-6无显著变化(P＞0.05);相应时间点,重建组的早期VAS评分、CRP、IL-6水平均显著优于钩板组(P＜0.05).所有患者术后平均随访(22.2±2.5)个月,两组患者恢复完全负重活动时间的差异无统计学意义(P＞0.05).随时间推移,两组患者的UCLA肩关节功能评分、肩关节外展上举、前屈上举、内外旋ROM均显著增加(P＜0.05).末次随访时,重建组的UCLA评分[(32.5±3.7)vs(29.1±3.1),P=0.002]、外展上举ROM[(151.4± 10.4)° vs(135.6±12.4)°,P＜0.001]、内旋 ROM[(62.9±13.0)° vs(52.1±11.4)°,P=0.004]和外旋 ROM[(66.6±9.4)° vs(57.0±9.4)°,P＜0.001]均显著优于钩板组.影像方面,术后3个月及末次随访时两组患者的喙锁距离(coracoclavicular distance,CC)和肩锁距离(acromioclavicular distance,AC)均较术前显著减小(P＜0.05).相应时间点,两组间CC和AC的差异均无统计学意义(P＞0.05).[结论]相比于钩板组治疗Rockwood Ⅲ型肩锁关节脱位,重建组具有创伤小、术后恢复快、术后疼痛轻微、术后炎症水平低等优点,还可有效改善患者肩关节功能和肩关节活动度,提升肩锁关节复位效果.

目的 评价屈曲90°位膝关节镜下双后内侧入路治疗腘窝囊肿的临床疗效.方法 选取我院2017年5月至2020年5月行关节镜手术治疗膝关节腘窝囊肿的30例病人,均于屈曲90°膝关节位行双后内侧入路,刨除后关节囊反折,使单向活瓣变为双向通道,并对囊壁进行清理.通过术后1周内及末次随访时复查的MRI来检验腘窝囊肿的复发情况;通过比较手术前后的Rauschning-Lindgren腘窝囊肿分级标准来评估临床疗效.结果 关节镜探查发现,所有病人都合并关节内损伤,其中大部分为半月板退变性损伤(70％).平均随访10个月(8～13个月),术后1周及末次随访时的MRI都未显示囊肿复发;术后1个月和末次随访的Rauschning-Lindgren分级均较术前明显改善,差异有统计学意义(P＜0.05).结论 屈膝90°位固定,关节镜下双后内侧入路治疗腘窝囊肿,疗效确切,安全可靠.

Osteoarthritis (OA) has a high incidence rate in the elderly population and is a cause of chronic degenerative joint disease. Current therapeutic approaches to OA are effective but come with some side effects. Therefore, it is urgent to find new safe and effective OA treatments. This study aimed to clarify the function of taraxasterol (TAX) isolated from Taraxacum officinale in the papain-induced rat OA model. We observed that TAX alleviated the typical OA-caused phenomena in the joint. The expression of serum inflammatory mediators such as TNF-α, IL-6, and IL-1β was also repressed by TAX. In addition, NF-κB signaling pathway was repressed by TAX. Furthermore, two microRNAs: miR-140 and miR-146a were elevated after TAX treatment in OA rat model. Interestingly, several common targets of miR-140 and miR-146a, including HSPA4L, ST5, and ERBB4, were confirmed to be regulated by TAX. Inflammatory response related genes including S100A8, CCL3, A2M, LBP, and CCR1 were repressed by TAX in OA rat model. In summary, TAX inhibits inflammation in osteoarthritis rat model. Inflammatory mediators, NF-κB pathway and miR-140/miR-146a targets mediate the function of TAX.

N6-methyladenosine (m6A) is one of the most significant modifications in human mRNAs. Emerging evidence indicates that m6A participates in the initiation and development of malignant tumors. Nevertheless, the biological roles and mechanism of m6A in osteosarcoma (OS) remain unclear. The purpose of this study was to investigate the role and mechanism of the methylation recognition protein-YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) in OS. The YTHDF1 expression in OS was detected by qRT-PCR and Western blot assay. M6A quantification was utilized to measure the methylation level of OS. Cell counting kit-8 (CCK8), 5-Ethynyl-2'-deoxyuridine (EdU) assay and transwell experiments were conducted to confirm the biological effects of YTHDF1 on OS cells. The bioinformatics websites and in vitro assays were conducted to analyze the downstream targets of YTHDF1 was upregulated in OS tissues at mRNA and protein level. The results showed that the expression level of YTHDF1 might be closely associated with the poor prognosis for OS patients. Inhibition of YTHDF1 could suppress the proliferation, migration and invasion of the OS cells. Moreover, we found that CCR4-NOT transcription complex subunit 7 (CNOT7) might be the potential target of YTHDF1, which was upregulated in OS tissues. YTHDF1 could recognize the m6A sites of CONT7 and promote its expression in an m6A manner. Moreover, methyltransferase-like 3 (METTL3) could promote the m6A level of CONT7. YTHDF1 was upregulated in OS and could promote cell proliferation, migration and invasion. The METTL3-CONT7-YTHDF1 regulatory axis might be the potential target for the prognosis and therapy of OS.

骨折是临床中常见的损伤,每年因骨折造成身体残疾和巨大的社会经济负担难以计数.骨折愈合过程极其复杂,受多种因素影响,包括全身与局部,骨折发生延迟愈合或不愈合率达5％～10％[1].研究显示,中医药可调节骨的代谢和形成,促进骨折的愈合[2].中药外治法治疗骨折具有悠久的历史,具有疗效显著,副作用小,无明显禁忌症等特点,可作为临床治疗骨折的有效方法.近年来,随着科技的进步,中药外治法治疗骨折也有新的进展,综述如下.

The purpose of this study was to compare the efficacy of teriparatide (parathyroid hormone 1-34) alone and in combination with zoledronic acid (ZA) for the treatment of osteoporosis in postmenopausal women. Ninety-six patients were randomly equally divided into Groups A (n=48) and B (n=48). Group A was given parathyroid hormone 1-34 alone. Group B was treated with parathyroid hormone 1-34 plus ZA. Visual analogue scale (VAS) score, bone mineral density(BMD), serum osteopontin (OPN), and C-terminal cross-linking telopeptide of type I collagen (S-CTX) etc. were compared. After 6 months of treatment, VAS score, serum OPN and S-CTX levels in Group B were significantly lower than those in Group A (p=0.001, p<0.001 and p<0.001, respectively); and BMD values of lumbar vertebrae L2-4, femoral neck and total hip bone in Group B were higher than those of Group A (p=0.002, p=0.028 and p<0.001, respectively). In conclusion, parathyroid hormone 1-34 plus ZA is more effective than parathyroid hormone 1-34 alone in treating post postmenopausal osteoporosis. Key Words: Teriparatide (parathyroid hormone 1-34, Zoledronic acid (ZA), Postmenopausal, Osteoporosis, Bone mineral density (BMD).

Total hip arthroplasty and total knee arthroplasty are extensively used for the treatment of the end-stage degenerative joint diseases. Currently, periprosthetic bone loss is still the major cause of aseptic loosening, resulting in implant failures. Previous literature introduced some widely accepted protocols for the prevention and treatment of periprosthetic bone loss, but no guideline has been proposed. Denosumab, a human monoclonal immunoglobulin G2 (IgG2) antibody, can inhibit bone resorption by binding to the receptor activator of nuclear factor kappa-B ligand (RANKL). This article reviews the present findings and evidence concerning the effect of denosumab on the periprosthetic bone loss after total hip arthroplasty and total knee arthroplasty. Overall, the current evidence suggests that denosumab is a promising agent for the treatment of periprosthetic bone loss.

青少年特发性脊柱侧凸(adolescent idiopathic scoliosis,AIS)是临床最常见的脊柱三维畸形,可严重影响患者的生活质量和心理健康.矫形器治疗是目前唯一被认可的能阻止AIS自然进程的非手术疗法,但目前临床中应用的矫形器种类繁多,临床选择和使用缺乏统一标准.本文从AIS矫形器的作用机制、适应证、分类及临床常用的AIS矫形器4个方面对AIS矫形器的研究进展进行了综述.

膝关节自发性复发性出血非常罕见,主要发生于合并骨关节炎的高龄人群.这类血肿最早由Wilson[1]报道,其认为滑膜炎症是出血的原因,因此滑膜切除术即是最合理的治疗方案[2?3].然而,Kawamura等[4]在1994年报道了5例伴有外侧半月板后角退变性撕裂的膝关节自发性出血病人,在经过关节镜下撕裂半月板切除术后,这5例病人均未出现复发,从而证实,膝关节自发性复发性出血来源于外侧半月板后角的周围动脉.此后,又有一些报道证实了这一理论[5?8],其中Sasho等[7]在切除半月板的过程中还探查到了搏动的动脉出血,考虑为膝外侧动脉的分支.但作为出血来源,其动脉本身结构从未被发现过.我们于2019年5月收治了一例膝关节自发性复发性出血病人,并在关节镜术中于关节囊的后外侧角发现了一个管状的搏动性出血结构,亦在内侧半月板前角发现带血管的滑膜攀附,现报告如下.

慢性踝关节不稳可导致踝关节反复扭伤,病情严重时需行手术治疗.对慢性踝关节不稳患者的步态动力学特征进行研究,可以为该病的治疗和疗效评价提供客观依据.本文对慢性踝关节不稳患者的步态动力学特征及平衡训练研究进展进行了综述.

ER oxidoreduclin 1α (ERO1α), an oxidase that exists in the ER, participates in protein folding and secretion and inhibiting apoptosis, and regulates tumor progression, which is a novel factor of poor cancer prognosis. However, the other physiological functions of ERO1α remain undiscovered. Although our preliminary results of this study indicated that ERO1α revealed the robust expression in ovary, especially in granulosa cells, the role of ERO1α in follicular development is not well known. Therefore, the aims of the present study were to explore the role of ERO1α and the possible mechanisms in regulating cell apoptosis and steroidogenesis in ovarian granulosa cells. ERO1α was mainly localized in granulosa cells and oocytes in the adult ovary by immunohistochemistry. Western blot analysis showed that the expression of ERO1α was highest at oestrous stage during the estrous cycle. The effect of ERO1α on cell apoptosis and steroidogenesis was detected by transduction of ERO1α overexpression and knockdown lentiviruses into primary cultured granulosa cells. Flow cytometry analysis showed that ERO1α decreased granulosa cells apoptosis. Western bolt and RT-qPCR analysis found that ERO1α increased the ratio of BCL-2/BAX, and decreased BAD and Caspase-3 expression. ELISA analysis showed that ERO1α enhanced estrogen (E2) secretion. Western bolt and RT-qPCR analysis found that ERO1α increased StAR, CYP11A1, 3β-HSD, CYP17A1, and CYP19A1 expression, and decreased CYP1B1 expression. Furthermore, Western bolt analysis found that ERO1αincreased PDI and PRDX 4 expression, and activated the PI3K/AKT/mTOR signaling pathway through increasing the phosphorylation of AKT and P70 S6 kinase. In summary, these results suggested that ERO1α might play an anti-apoptotic role and regulate steroidogenesis in granulosa cells, at least partly, via activation of the PI3K/AKT/mTOR signaling pathway.

背景:以往有关全膝关节置换治疗类风湿关节炎临床疗效的研究报道较多,而关于全膝关节置换对类风湿关节炎患者关节功能及相关生化指标的影响研究较少,因此需要更多的临床证据支持.目的:分析全膝关节置换治疗类风湿关节炎对患者关节功能及相关生化指标的影响.方法:选取接受全膝关节置换的患者64例(64膝),回顾性分析患者的临床资料.对比分析术前与术后1年患者美国特种外科医生膝关节评分、膝关节活动度及生活质量评分结果,检测患者C-反应蛋白、类风湿因子及血沉等生化指标的变化,并记录患者术后1个月并发症发生情况.该研究已获得常州市中医医院医学伦理委员会批准,所有患者均签署知情同意书.结果 与结论:①与术前相比,患者术后1年HSS评分、膝关节活动度、生活质量评分明显升高(P＜0.01),C-反应蛋白、类风湿因子及血沉水平明显降低(P＜0.01);②术后1例患者发生感染,2例患者出现下肢深静脉血栓,经对症治疗后得到缓解.结果 证实,全膝关节置换对类风湿关节炎有较好的临床效果,可改善患者膝关节功能,降低C-反应蛋白、类风湿因子及血沉水平,具有良好的安全性.

BACKGROUND:Intra-articular corticosteroid injections have been widely used and are considered a mainstay in the nonoperative treatment of symptomatic knee osteoarthritis (OA). However, their increased use can have negative implications, including chondral toxicity and a high risk of infections. As a result, nonsteroidal anti-inflammatory drugs have been considered as an alternative. PURPOSE:To determine the pain relief and safety of ketorolac versus a corticosteroid to supplement an intra-articular sodium hyaluronate injection for the treatment of symptomatic knee OA. STUDY DESIGN:Cohort study; Level of evidence, 3. METHODS:A total of 84 patients with unilateral symptomatic knee OA receiving 5 weekly injections were enrolled in this retrospective study. Group A (n = 42) received 3 weekly intra-articular corticosteroid injections (0.5% lidocaine, 25 mg of triamcinolone acetonide, and 25 mg of sodium hyaluronate, followed by 2 weekly injections of 0.5% lidocaine and 25 mg of sodium hyaluronate), while group B (n = 42) received 5 weekly ketorolac injections (0.5% lidocaine, 10 mg of ketorolac, and 25 mg of sodium hyaluronate). The following parameters were used to evaluate pain relief and safety: visual analog scale (VAS) for pain, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and side effects before the injection and at 1, 2, and 5 weeks after treatment commencement as well as 3 months after the last injection. RESULTS:Patients from both groups had a significant improvement in VAS and WOMAC scores from the first injection to final follow-up at 3 months. In the first week, the VAS score was lower in group A (P = .041), but no significant between-group differences were found for either the VAS or the WOMAC score at the other time points. Of the 42 patients in group A, 34 (81.0%) and 25 (59.5%) achieved successful outcomes at 5 weeks after treatment commencement and 3 months after the last injection, respectively. In group B, 32 (76.2%) and 24 (57.1%) patients achieved successful outcomes at 5 weeks after treatment commencement and 3 months after the last injection, respectively. At final follow-up, no significant difference was found in the successful treatment rate between the groups (P = .825). CONCLUSION:The current study demonstrated that intra-articular ketorolac and corticosteroid injections produce the same pain relief and functional improvement.

MiR-20a has been reported as a key regulator to pro-inflammatory factor release in fibroblast-like synoviocytes (FLS), which caused rheumatoid arthritis (RA). However, the molecular mechanism of miR-20a in RA remains to be further elucidated. This study aimed to investigate the roles of miR-20a in RA pathology. RA (n = 24) and osteoarthritis (OA, n = 20) and normal healthy tissues (n = 16) were collected from operation. TargetScan and dual-luciferase reporter were performed to predict and confirm the potential binding sites of miR-20a on ADAM metallopeptidase domain 10 (ADAM10). Pearson's analysis was adopted to evaluate the correlation between miR-20a and ADAM10 expression. It was found that MiR-20a was downregulated in RA tissues, and overexpressed miR-20a inhibited cell viability, migration and invasion, and the expression of inflammatory factors in RA-FLS MH7A cells. ADAM10 was identified as the target gene of miR-20a, and upregulation of ADAM10 reversed the inhibitory effects of miR-20a. In conclusion, miR-20a inhibits the progression of RA-FLS as well as the inflammatory factor expression by targeting ADAM10.

目的:探讨超声引导下行腰丛复合坐骨神经阻滞麻醉应用于老年股骨粗隆间骨折手术的效果.方法:选择老年股骨粗隆间骨折110例,按照随机数字表法分为观察组和对照组,各55例.对照组行蛛网膜下腔阻滞麻醉复合硬膜外麻醉,观察组行超声引导下腰丛复合坐骨神经阻滞麻醉.比较2组神经阻滞起效时间、维持时间和手术前后免疫球蛋白水平、疼痛程度及麻醉不良反应发生率.结果:观察组病人感觉神经和运动神经的阻滞起效时间均明显短于对照组(P<0.01),维持时间均明显长于对照组(P<0.01).术前,2组病人IgG、IgM、IgE水平差异均无统计学意义(P>0.05);术后6、24、72 h,观察组IgG、IgM、IgE水平均明显高于对照组(P<0.01).术后6、12、24 h,观察组病人VAS评分均明显低于对照组(P<0.01);术后72 h,2组病人VAS评分差异无统计学意义(P>0.05).观察组麻醉不良反应总发生率为14.55％(8/55),低于对照组的34.55％(19/55)(P<0.05).结论:超声引导下行腰丛复合坐骨神经阻滞麻醉应用于老年股骨粗隆间骨折手术可缩短麻醉起效时间,减少对病人机体免疫功能负面影响,减轻术后疼痛,降低不良反应发生率,值得临床应用推广.

[目的]研究 3D设计矫形鞋垫及医学运动锻炼对跖筋膜炎患者足底疼痛及足部功能的影响.[方法]选取本院骨科 2017 年 9 月至 2018 年 9 月收治的 80 例(131 足)跖筋膜炎患者为研究对象,以随机数表法分为观察组与对照组,各40 例.观察组采取 3D设计矫形鞋垫联合医学运动锻炼干预,对照组采取单纯医学运动锻炼干预.对比两组干预前后足部功能障碍恢复情况(包括足部疼痛和行动障碍),对比两组干预前后足部功能评分(AOFAS)、足部功能障碍评分,另对比两组干预前后跖筋膜厚度、最长持续行走时间差异.[结果]观察组干预后 AOFAS评分显著高于干预前及对照组干预后,差异有统计学意义(P ＜0.05);观察组优良率 73.00%显著高于对照组(35.00%),差异有统计学意义(P ＜0.05).观察组干预后足部疼痛程度及行动障碍程度评分显著低于干预前及对照组干预后,差异有统计学意义(P ＜0.05).观察组干预后跖筋膜厚度显著低于干预前及对照组干预后,差异有统计学意义(P ＜0.05);观察组干预后最长持续行走时间显著长于干预前及对照组干预后,差异有统计学意义(P ＜0.05).[结论]3D 设计矫形鞋垫配合医学运动锻炼可有效缓解患者的足部疼痛及行动障碍,干预效果较好,值得临床推广使用.

目的 探究脊柱平衡疗法应用于青少年特发性脊柱侧凸病人中的效果.方法 选取2016年7月至2017年7月常州市中医医院收治的给予常规疗法(佩戴支具)的青少年特发性脊柱侧凸病人60例作为对照组,另选取2017年8月至2018年8月该院收治的给予脊柱平衡疗法(对病人进行脊柱平衡导引训练、脊柱平衡推拿正骨等)的青少年特发性脊柱侧凸病人60例作为观察组,疗程均为6个月.对比两组凸凹侧表面平均肌电(AEMG)比值与脊柱侧弯角度(Cobb角)、肺功能改善情况及临床疗效.结果 观察组干预6个月后凸凹侧AEMG比值为(1.09±0.16),低于对照组的(1.63±0.45)(P<0.001),观察组Cobb角为(9.08±1.43)°小于对照组的(10.32±2.11)°(P<0.001);观察组干预6个月后用力肺活量(FVC)为(93.21±4.54)L、第1秒用力呼气容积占用力肺活量的百分比(FEV1/FVC)为(93.01±3.65)L、每分钟最大通气量(MVV)为(75.46±3.27)L,均高于对照组的(87.64±4.02)、(88.03±4.38)、(70.65±4.51)L(P<0.001);观察组干预6个月后临床总疗效为95.00％,高于对照组的80.00％(P<0.05).结论 脊柱平衡疗法应用于青少年特发性脊柱侧凸病人中,可显著改善其凸凹侧AEMG比值,降低Cobb角,改善其肺功能,并有效提高其临床疗效,值得推广.